Acetaminophen plasma level after oral administration in liver cirrhotic patients suffering from schistosomal infection

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 7, 1996, Pages 299-303

  El Azab, G ^a,b   Youssef, M K ^b   Higashi, Y ^a   Murakami, T ^a   Yata, N ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b Tanta University   (Egypt)

Author keywords

Acetaminophen; First pass metabolism; Hepatic schistosomiasis; Liver cirrhotic patient; Oral bioavailability

Indexed keywords

PARACETAMOL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; SCHISTOSOMIASIS; SCHOOL CHILD;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; AGING; ANALGESICS, NON-NARCOTIC; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHILD; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SCHISTOSOMIASIS;

EID: 0030037514     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Black M 1974 Liver disease and drug therapy. Med Clin North Am 58: 1051-1057
2. Cha YN, Edwards R 1976 Effect of schistosoma mansoni infection on hepatic drug metabolizing capacity of mice. J Pharm Exp Ther 199: 432-440
3. Chin N, Ohnishi K, Iida S, Nomura F 1988 Role of intrahepatic portalsystemic shunts in the reduction of portal blood supply to liver cells in cirrhosis. Am J Gastroenterol 83: 718-722
4. Chiou WI 1975 Estimation of hepatic first pass effect of acetaminophen in human after oral administration. J Pharm Sci 64: 1734-1735
5. Editorial 1973 Safe prescribing in liver disease. Br Med J 2: 193-194
6. El-Mouelhi M, Mansour M 1990 Hepatic drug conjugation/deconjugation system in hepatosplenic schistosomiasis. Biochem Pharmacol 40: 1923-1925
7. Faigle JW 1971 Blood levels of schistosomocide in relation to liver functions and side effects. Acta Pharmacol Toxicol 29: 233-239
8. Ghazal A, Mahfouze M, Ghoneim A 1974 Effect of schistosomicidal drugs on the drug metabolizing enzymes of mouse liver. Naunyn Schmiedebergs Arch Pharmacol 282: 181-186
9. Gilman G, Goodman L, Gilman A 1980 The pharmacological basis of therapeutics. Macmillan, New York, pp 702-703
10. Higuchi M, Ito Y, Fukuyama K, Epstein W 1984 Biochemical characterization of aryl sulfatases detected in granulamatous inflammation. Exp Mol Pathol 40: 70-78
11. Laidlaw J, Read AE, Sherloch S 1961 Morphine tolerance in hepatic cirrhosis. Gastroenterology 40: 389-396
12. Moreno AM, Burchell AR, Rousselot WF 1967 Portal blood flow in cirrhosis of the liver. J Clin Invest 45: 436-444
13. Neal E, Meffin P, Gregory P, Blaschke T 1979 Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 77: 96-102
14. Nompleggi D, Farraye F, Singer A, Edelman R, Chopra S 1991 Hepatic schistosomiasis: Report of two cases and literature review. Am J Gastroenterology 86: 1658-1664
15. Perucca E, Richens A 1979 Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br J Clin Pharmacol 7: 201-206
16. Pessayre D, Lebrec D. Descatoire V, Peignoux M, Benhamou J 1978 Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology 74: 566-571
17. Rawlins MD, Henderson DB, Hijab AR 1977 Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol 11: 283-286
18. Schenker S, Hoyumpa AM, Wilkinson GR 1975 Effect of parenchymal liver disease on the disposition and elimination of sedatives and analgesics. Med Clin North Am 59: 887-896
19. Zimmon DS 1977 The hepatic vasculature and its response to hepatic injury: A working hypothesis. J Biol Med 50: 497-506